Nurix Therapeutics: Julia P. Gregory sells 22,583 shares

The option became fully vested on August 12, 2023, before the 22,583-share exercise.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) director Julia P. Gregory exercised a director stock option for 22,583 shares of common stock on October 14, 2026, at $1.86 per share, then sold 22,583 shares at a weighted average price of $23.4038. Sale prices ranged from $23.34 to $23.62. The director stock option had a reported post-exercise balance of 0 shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 22,583 shares ($487K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider GREGORY JULIA P

Role Director

Sold 22,583 shs ($529K)

Approx. gross sale proceeds $529K

Approx. exercise cost $42K

Approx. pre-tax spread $487K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy) F2	22,583	$0.00	$0.00
Exercise	Common Stock	22,583	$1.86	$42K
Sale	Common Stock F1	22,583	$23.4038	$529K

Holdings After Transaction: Director Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 10,750 shares (Direct)

Footnotes (2)

1. F1. Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
2. F2. The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023.

Key Figures

Options exercised: 22,583 shares Exercise price: $1.86 per share Common shares acquired on exercise: 22,583 shares +4 more

7 metrics

Options exercised 22,583 shares October 14, 2026

Exercise price $1.86 per share Options exercised October 14, 2026

Common shares acquired on exercise 22,583 shares October 14, 2026

Common shares sold 22,583 shares October 14, 2026

Weighted average sale price $23.4038 per share Sale on October 14, 2026

Sale price range $23.34-$23.62 per share Sale on October 14, 2026

Reported director stock option balance after exercise 0 shares Following the October 14, 2026 exercise

Key Terms

weighted average sale price, Director Stock Option (right to buy), fully vested

3 terms

weighted average sale price financial

"Represents the weighted average sale price."

Director Stock Option (right to buy) financial

"Director Stock Option (right to buy)"

fully vested financial

"until the option was fully vested on August 12, 2023."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares did Julia P. Gregory sell, and at what price?

Julia P. Gregory sold 22,583 shares at a weighted average price of $23.4038 per share on October 14, 2026. The sale prices ranged from $23.34 to $23.62.

When did Julia P. Gregory's NRIX stock option vest?

The option vested as to 1/48 of the total shares monthly beginning September 12, 2019, and became fully vested on August 12, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 04:12 PM EDT Accepted by SEC EDGAR 10/14/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GREGORY JULIA P

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/14/2026		M		22,583	A	$1.86	33,333	D
Common Stock	10/14/2026		S		22,583	D	$23.4038(1)	10,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$1.86	10/14/2026		M			22,583	(2)	12/22/2029	Common Stock	22,583	$0	0	D

Explanation of Responses:

1. Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

2. The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)